Oruka Therapeutics, Inc. filed a Form 8-K on August 24, 2026, disclosing the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026, pursuant to a letter agreement dated July 22, 2026.
Key Highlights
- New hire: Todd Edwards, age 63, commenced employment as Chief Commercial Officer on August 24, 2026.
- Base salary: Mr. Edwards will receive an annualized base salary of $525,000, with a discretionary bonus targeted at 40% of his annual base salary.
- Signing bonus: A $200,000 signing bonus is payable within 30 days of his commencement of employment, subject to prorated repayment if he resigns or is terminated for cause within the first year.
- Equity grants: Mr. Edwards received a stock option covering 20,000 shares and restricted stock units covering 100,000 shares of Oruka common stock.
- Prior experience: Mr. Edwards most recently served as Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, Inc. from December 2024 to August 2026.
- Severance terms: In the event of termination without cause or resignation with good reason, Mr. Edwards is eligible to receive 12 months of base salary and up to 12 months of company-paid health coverage.
Compensation and Severance Details for Oruka's New CCO
According to the filing, Oruka Therapeutics, Inc. (NASDAQ:ORKA) entered into a letter agreement with Todd Edwards on July 22, 2026, under which he commenced employment as Chief Commercial Officer on August 24, 2026. Mr. Edwards brings prior commercial leadership experience from Arcutis Biotherapeutics, Incyte Corporation, and UCB S.A., where he held senior roles across immunology, dermatology, rheumatology, and gastroenterology. He also held senior positions at AbbVie and TAP Pharmaceuticals. The filing notes that Mr. Edwards is a decorated veteran of the U.S. Army and holds a B.S. in Psychology from East Tennessee State University and an M.B.A. from Embry-Riddle Aeronautical University.
The filing discloses that Mr. Edwards' stock option covering 20,000 shares will vest as to 25% of the underlying shares on August 24, 2027, with the remainder vesting in approximately equal monthly installments over the following 36 months. His RSUs covering 100,000 shares will vest as to 25% on the first Oruka quarterly vesting date following August 24, 2027, with the balance vesting in 12 equal quarterly installments thereafter.
The filing further states that if an involuntary termination occurs within three months before or 12 months after a change in control of Oruka, Mr. Edwards would instead receive severance equal to 1.0 times the sum of his base salary and target bonus, up to 12 months of company-paid health coverage, and full acceleration of outstanding time-based equity awards. The filing also notes that if Mr. Edwards' employment terminates due to death or disability, his outstanding time-based equity awards will become fully vested. The filing states there are no family relationships between Mr. Edwards and any director or executive officer of Oruka.
What Was Disclosed
Oruka Therapeutics disclosed the appointment of Todd Edwards as Chief Commercial Officer, including the terms of his compensation, equity grants, signing bonus, and severance arrangements, as reported in a Form 8-K filed August 24, 2026.




Please wait processing your request...